A personal care composition
A personal care composition with carboxymethyl cysteine and urea in a 40:1 ratio synergistically upregulates the filaggrin 2 gene, addressing the need for enhanced skin health by improving filaggrin production and skin barrier integrity.
Patent Information
- Application Number
- PCT/EP2026/058023
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-06-13
- Filing Date
- 2026-03-23
- Publication Date
- 2026-11-12
AI Technical Summary
Existing personal care compositions fail to effectively upregulate the expression of the filaggrin 2 gene (FLG2), which is crucial for maintaining skin health and barrier integrity, leading to conditions like dryness and atopic dermatitis.
A personal care composition comprising carboxymethyl cysteine and urea compounds in a specific weight ratio of no greater than 40:1 synergistically upregulates the expression of the filaggrin 2 gene (FLG2).
The composition significantly enhances filaggrin production and improves skin barrier health by upregulating the FLG2 gene expression, providing at least a 2-fold increase compared to individual use of these compounds.
Smart Images

Figure IMGF000010_0001_TABLE
Abstract
Description
[0001] P0001302W01 CPL
[0002] 1
[0003] A PERSONAL CARE COMPOSITION
[0004] Field of the Invention
[0005] The present invention relates to a personal care composition comprising carboxymethyl cysteine compound and urea compound. It was unexpectedly found that the FLG2 gene expression is capable of being synergistically upregulated when the weight ratio of the urea compound to the carboxymethyl cysteine compound is no greater than 40:1.
[0006] Background of the Invention
[0007] Skin is an organ that protects the body from external stressors like heat, UV, pollutants, allergens, pathogens etc. It also prevents loss of moisture. The protective role of skin is carried out by epidermal or skin barrier. The skin barrier consists of different layers of stratified cells and the outermost layer consists of corneocytes embedded in a layer of lipids. The major constituents of corneocytes are proteins like keratin, filaggrin etc. These proteins are essential for the formation and maintenance of a healthy skin barrier. Any damage or dysfunction of these proteins lead to defective barrier and associated skin conditions like dryness, atopic dermatitis increased susceptibility to skin infections, inability to support a healthy microbiome etc.
[0008] Among the skin proteins, filaggrin play a pivotal role in maintaining healthy barrier. It is a structural protein involved in the terminal differentiation of keratinocytes. Proteolysis of filaggrin releases free amino acids and these free amino acids are the important constituents of natural moisturization factor (NMF) which imparts skin hydration. Filaggrin maintains barrier integrity thereby preventing entry of pathogens, and other irritants and allergens. Loss of filaggrin results in skin conditions like atopic dermatitis, an inflammatory skin condition manifested as dry, itchy and flaky skin. Filaggrin also helps in maintaining a healthy microbiome by protecting the skin from pathogens. One of the mechanisms by which moisturizers function is by boosting filaggrin in skin. Increasing filaggrin levels on skin is a well-accepted approach for maintaining or improving skin health. Upregulating the expression of filaggrin genes typically leads to an increase in filaggrin production.
[0009] Therefore, the present inventors have recognized that there is a need to develop solution to enhance the expression of filaggrin 2 gene (FLG2). It was surprisingly found that by combining carboxymethyl cysteine and urea compound with a weight ratio of the urea compound to the carboxymethyl cysteine compound being no greater than 40:1, the expression of FLG2 gene was significantly upregulated.P0001302W01 CPL
[0010] 2
[0011] Summary of the Invention
[0012] In a first aspect, the present invention is directed to a personal care composition comprising (a) carboxymethyl cysteine compound and (b) urea compound, wherein the weight ratio of the urea compound to the carboxymethyl cysteine compound is no greater than 40:1.
[0013] In a second aspect, the present invention is directed to a method of providing the skin benefits selected from the group consisting of enhancing filaggrin production in the skin, improving skin barrier health, upregulating the expression of filaggrin 2 gene comprising a step of topically applying to the skin the composition of the present invention.
[0014] In a third aspect, the present invention is directed to use of the composition of the present invention for providing the skin benefits selected from the group consisting of enhancing filaggrin production in the skin, improving skin barrier health, upregulating the expression of filaggrin 2 gene.
[0015] All other aspects of the present invention will more readily become apparent upon considering the detailed description and examples which follow.
[0016] Detailed Description of the Invention
[0017] Except in the examples, or where otherwise explicitly indicated, all numbers in this description indicating amounts of material or conditions of reaction, physical properties of materials and / or use may optionally be understood as modified by the word “about”.
[0018] All amounts are by weight of the composition, unless otherwise specified.
[0019] It should be noted that in specifying any range of values, any particular upper value can be associated with any particular lower value.
[0020] For the avoidance of doubt, the word “comprising” is intended to mean “including” but not necessarily “consisting of’ or “composed of”. In other words, the listed steps or options need not be exhaustive.
[0021] The disclosure of the invention as found herein is to be considered to cover all embodiments as found in the claims as being multiply dependent upon each other irrespective of the fact that claims may be found without multiple dependency or redundancy.P0001302W01 CPL
[0022] 3
[0023] Where a feature is disclosed with respect to a particular aspect of the invention (for example a composition of the invention), such disclosure is also to be considered to apply to any other aspect of the invention (for example a method of the invention) mutatis mutandis.
[0024] The carboxymethyl cysteine compound refers to compound selected from carboxymethyl cysteine, salt of carboxymethyl cysteine, ester of carboxymethyl cysteine, amide of carboxymethyl cysteine or a mixture thereof. Preferably, the carboxymethyl cysteine compound comprises carboxymethyl cysteine, ester of carboxymethyl cysteine, and / or salt of carboxymethyl cysteine. More preferably, the carboxymethyl cysteine compound comprises carboxymethyl cysteine, and / or salt of carboxymethyl cysteine. Even more preferably, carboxymethyl cysteine compound comprises salt of carboxymethyl cysteine. Still even more preferably the carboxymethyl cysteine compound comprises lysine carboxymethyl cysteinate and most preferably, the carboxymethyl cysteine compound is lysine carboxymethyl cysteinate.
[0025] Preferably, the carboxymethyl cysteine compound is present in amount of at least 0.000002%, more preferably at least 0.00002%, even more preferably at least 0.0002%, still even more preferably at least 0.002%, and most preferably at least 0.02% by weight of the composition. Preferably, the carboxymethyl cysteine compound is present in amount of no greater than 5%, more preferably no greater than 3%, even more preferably no greater than 1%, still even more preferably no greater than 0.6%, and most preferably no greater than 0.3% by weight of the composition.
[0026] Preferably, the lysine carboxymethyl cysteinate is present in amount of at least 0.000002%, more preferably at least 0.00002%, even more preferably at least 0.0002%, still even more preferably at least 0.002%, and most preferably at least 0.02% by weight of the composition. Preferably, the lysine carboxymethyl cysteinate is present in amount of no greater than 5%, more preferably no greater than 3%, even more preferably no greater than 1%, still even more preferably no greater than 0.6%, and most preferably no greater than 0.3% by weight of the composition.
[0027] The composition of the present invention comprises urea compound. Urea compound as used herein refers to urea, or urea with at least one hydrogen substituted by alkyl or hydroxyalkyl group, preferably by Ci-Ce alkyl or Ci-Ce hydroxyalkyl group. Preferably, the urea compound is selected from urea, and urea with at least one hydrogen substituted by hydroxyalkyl group, preferably by Ci-Ce hydroxyalkyl group. More preferably, the urea compound is selected fromP0001302W01 CPL
[0028] 4
[0029] urea, and urea with at least one hydrogen substituted by Ci-Ce hydroxyalkyl group. Even more preferably, the urea compound is urea with at least one hydrogen substituted by Ci-Ce hydroxyalkyl group. Still even more preferably, the urea compound is selected from hydroxymethyl urea, hydroxyethyl urea, hydroxypropyl urea; bis(hydroxymethyl)urea; bis(hydroxyethyl)urea; bis(hydroxypropyl)urea; N,N'-di hydroxymethyl urea; N,N'-di-hydroxyethyl urea; N,N'-di- hydroxypropyl urea; N,N,N'-tri-hydroxyethyl urea; tetra(hydroxymethyl)urea; tetra(hydroxyethyl)urea; tetra(hydroxypropyl urea; N-methyl, N'-hydroxyethyl urea; N- ethyl-N'-hydroxyethyl urea; N-hydroxypropyl-N'-hydroxyethyl urea and N,N'-dimethyl-N- hydroxyethyl urea or a mixture thereof. Where the term hydroxypropyl appears, the meaning is generic for either 3-hydroxy-n-propyl, 2-hydroxy-n-propyl, 3-hydroxy-i-propyl or 2-hydroxy-i-propyl radicals. Most preferably the urea compound is hydroxyethyl urea.
[0030] Preferably, the urea compound is present in amount of from 0.000001 to 25% by weight of the composition, more preferably from 0.00005 to 18%, even more preferably from 0.0005 to 12%, still even more preferably from 0.01 to 8% and most preferably from 0.2 to 5% by weight of the composition.
[0031] Preferably the weight ratio of the urea compound to the carboxymethyl cysteine compound is 1:10 to 40:1, more preferably 1:5 to 40:1, even more preferably 1:3 to 25:1 and still even more preferably 3:1 to 20:1.
[0032] Preferably, the present invention provides a personal care composition comprising (a) carboxymethyl cysteine compound and (b) urea with at least one hydrogen substituted by Ci-Ce hydroxyalkyl group, wherein the weight ratio of the urea with at least one hydrogen substituted by Ci-Ce hydroxyalkyl group to the carboxymethyl cysteine compound is no greater than 40:1.
[0033] Preferably, the urea with at least one hydrogen substituted by Ci-Ce hydroxyalkyl group is present in amount of from 0.000001 to 25% by weight of the composition, more preferably from 0.00005 to 18%, even more preferably from 0.0005 to 12%, still even more preferably from 0.01 to 8% and most preferably from 0.2 to 5% by weight of the composition.
[0034] Preferably the weight ratio of the urea with at least one hydrogen substituted by Ci-Ce hydroxyalkyl group to the carboxymethyl cysteine compound is 1:10 to 40:1, more preferably 1:5 to 40:1, even more preferably 1:3 to 25:1 and still even more preferably 3:1 to 20:1.P0001302W01 CPL
[0035] 5
[0036] Preferably, the present invention provides a personal care composition comprising (a) carboxymethyl cysteine compound and (b) hydroxyethyl urea, wherein the weight ratio of the hydroxyethyl urea to the carboxymethyl cysteine compound is no greater than 40:1.
[0037] Preferably, the hydroxyethyl urea is present in amount of from 0.000001 to 25% by weight of the composition, more preferably from 0.00005 to 18%, even more preferably from 0.0005 to 12%, still even more preferably from 0.01 to 8% and most preferably from 0.2 to 5% by weight of the composition.
[0038] Preferably the weight ratio of the hydroxyethyl urea to the carboxymethyl cysteine compound is 1:10 to 40:1, more preferably 1:5 to 40:1, even more preferably 1:3 to 25:1 and still even more preferably 3:1 to 20:1.
[0039] Preferably, the present invention provides a personal care composition comprising (a) lysine carboxymethyl cysteinate and (b) hydroxyethyl urea, wherein the weight ratio of the hydroxyethyl urea to the lysine carboxymethyl cysteinate is no greater than 40:1.
[0040] Preferably the weight ratio of the hydroxyethyl urea to the lysine carboxymethyl cysteinate is 1:10 to 40:1, more preferably 1:5 to 40:1, even more preferably 1:3 to 25:1 and still even more preferably 3:1 to 20:1.
[0041] Preferably, the composition comprises fatty acid. Fatty acid as used herein refers to carboxylic acids with an aliphatic chain of at least 6 carbon atoms, preferably 6 to 30 carbon atoms. Preferably, the fatty acid is C8-C24 fatty acid, more preferably the fatty acid is C10-C22 fatty acid, even more preferably the fatty acid is unsubstituted C12-C20 fatty acid and still even more preferably the fatty acid is unsubstituted C12-C18 fatty acid. The term unsubstituted for unsubstituted fatty acid typically means the fatty acid radical is free from substituent groups such as OH, Cl or amino. The unsubstituted fatty acid can be branched or unbranched, preferably unbranched unsubstituted fatty acids.
[0042] Preferably, the fatty acid is saturated. Preferably, the fatty acid is selected from myristic acid, lauric acid, palmitic acid, stearic acid or a mixture thereof. More preferably, the fatty acid is selected from lauric acid, palmitic acid, stearic acid or a mixture thereof.P0001302W01 CPL
[0043] 6
[0044] For sake of clarity, the unsubstituted fatty acid also includes salt of the unsubstituted fatty acid, especially sodium salt thereof but preferably, the fatty acid is free fatty acid.
[0045] The amount of fatty acid in the composition is preferably from 0.000001 to 25% by weight of the composition, more preferably from 0.00001 to 7%, even more preferably from 0.0001 to 4%, still even more preferably from 0.001 to 2% and most preferably from 0.05 to 0.6% by weight of the composition.
[0046] Typically the weight ratio of the urea compound to the fatty acid is 1:400 to 400:1, preferably 1 : 150 to 150: 1 , more preferably 1 :40 to 40: 1 , even more preferably 1 : 15 to 15: 1 and still even more preferably 1:8 to 8:1.
[0047] Preferably, the composition comprises Vitamin B3 compounds. Vitamin B3 compound as used herein also comprises niacin, niacinamide, nicotinyl alcohol, derivatives thereof, salts of any of the foregoing, as well as mixtures thereof. Derivatives typically comprise nicotinic acid esters, nicotinyl alcohol esters of carboxylic acids, niacinamide N-oxide, nicotinyl amino acids and / or nicotinic acid n-oxide. The vitamin B3 compounds preferably comprises niacin, nicotinic acid, niacinamide or a mixture thereof. The most preferred vitamin B3 compound is niacinamide. Amount of Vitamin B3 compounds may be 0.005 to 10%, preferably 0.1 to 8%, more preferably 0.5 to 5% by weight of the composition. 2-mercaptonicotinoyl glycine may also be included in the composition. Amount of 2-mercaptonicotinoyl glycine may be 0.0001 to 10%, preferably 0.01 to 1% by weight of the composition.
[0048] Typically the weight ratio of the carboxymethyl cysteine compound to the Vitamin B3 compound is 1:1000 to 50:1, preferably 1:300 to 20:1, more preferably 1:120 to 2:1, even more preferably 1:80 to 1:1 and still even more preferably 1:50 to 1:5.
[0049] The composition may comprise substituted resorcinol. Substituted resorcinol typically refers to that at least one hydrogen on the ring structure and / or on a hydroxy group of the resorcinol replaced with an alkyl group, phenyl alkyl group, or heterocyclic group. Preferably, the substituted resorcinol is 4-substituted resorcinol. Preferably, the substituted resorcinol is selected from 4-ethyl resorcinol, 4-butyl resorcinol, 4-hexyl resorcinol, phenylethyl resorcinol, thiamidol, or a mixture thereof, more preferably, the substituted resorcinol is selected from 4-ethyl resorcinol, 4-butyl resorcinol, 4-hexyl resorcinol, or a mixture thereof and even more preferably, the substituted resorcinol comprises 4-hexyl resorcinol. The amount of theP0001302W01 CPL
[0050] 7
[0051] substituted resorcinol is preferably in the range of 0.00001 to 10%, more preferably from 0.001 to 5% and most preferably from 0.1 to 0.6% by weight of the total amount of the composition.
[0052] Preferably, the composition comprises a glutamate source selected from the group consisting of glutamine, glutamine ester, glutamic acid, pyroglutamic acid, salts, and mixtures thereof. More preferably, the composition comprises pyroglutamic acid and / or salt of pyroglutamic acid. Even more preferably, the composition comprises sodium salt of pyroglutamic acid. Preferably, the glutamate source is present in amount of 0.0001 to 10% by weight of the composition, more preferably 0.001 to 6%, even more preferably 0.01 to 3% by weight of the composition.
[0053] The composition may optionally comprise whitening pigment. Whitening pigments are typically particles of high refractive index materials. For example, the whitening pigment may have a refractive index of greater than 1.3, more preferably greater than 1.8 and most preferably from 2.0 to 2.7. Examples of such whitening pigment are those comprising bismuth oxy-chloride, boron nitride, barium sulfate, mica, silica, titanium dioxide, zirconium oxide, aluminium oxide, zinc oxide or combinations thereof. More preferred whitening pigment are particles comprising titanium dioxide, zinc oxide, zirconium oxide, mica, iron oxide or a combination thereof. Even more preferred whitening pigment are particles comprising zinc oxide, zirconium oxide, titanium dioxide or a combination thereof as these materials have especially high refractive index. Still even more preferably the whitening pigment is selected from titanium dioxide, zinc oxide or a mixture thereof and most preferred whitening pigment is titanium dioxide. The average diameter of whitening pigment is typical from 15 nm to 1 micron, more preferably from 35 nm to 800 nm, even more preferably from 50 nm to 500 nm and still even more preferably from 100 to 300 nm. Amount of whitening pigment may be 0.1 to 15%, preferably 0.5 to 5% by weight of the composition.
[0054] Preferably, the composition comprises polyhydric alcohol. Polyhydric alcohols may be selected from group of glycerin, propylyene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-butylene glycol, isoprene glycol, ethoxylated glycerol, propoxylated glycerol or a mixture thereof. Most preferred polyhydric alcohol is glycerol known also as glycerin. The amount of polyhydric alcohol may range anywhere from 0.1 to 20%, preferably 0.5 to 15% and more preferably 2 and 10% by weight of the composition.P0001302W01 CPL
[0055] 8
[0056] Preferably, the composition comprises emollient materials. Suitable emollient materials include silicones, hydrocarbons, triglycerides or a mixture thereof. These silicones may be organic, silicone-containing or fluorine-containing, volatile or non-volatile, polar or non-polar.
[0057] Hydrocarbons may include mineral oil, petrolatum and polyalpha-olefins. Examples of preferred volatile hydrocarbons include polydecanes such as isododecane and isodecane (e.g.
[0058] Permethyl-99A which is available from Presperse Inc.) and the C7-C8 through C12-C15 isoparaffins (such as the Isopar Series available from Exxon Chemicals). Illustrative triglycerides but not limiting are sunflower seed oil, cotton oil, canola oil, soybean oil, castor oil, borage oil, olive oil, shea butter, jojoba oil and mixtures thereof. Mono- and di- glycerides may also be useful. Particularly preferable are glyceryl monostearate and glyceryl distearate.
[0059] Preferably, the composition comprises moisturizing agents. Particularly preferred moisturizing agents includes, petrolatum, aquaporin manipulating actives, oat kernel flour, hyaluronic acid and / or its precursor N-acetyl glucosamine, or a mixture thereof.
[0060] Some compositions may include thickeners. These may be selected from cellulosics, natural gums and acrylic polymers but not limited by this thickening agent types. Among the cellulosics are sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose and combinations thereof. Suitable gums include xanthan, pectin, karaya, agar, alginate gums and combinations thereof. Among the acrylic thickeners are homopolymers and copolymers of acrylic and methacrylic acids including carbomers such as Carbopol 1382, Carbopol 982, llltrez, Aqua SF-1 and Aqua SF-2 available from the Lubrizol Corporation. Amounts of thickener may range from 0.01 to 3% by weight of the active polymer (outside of solvent or water) in the compositions.
[0061] In addition, the compositions of the invention may further include 0.5 to 10% by weight of sequestering agents, such as tetra sodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures; opacifiers and pearlizers such as ethylene glycol distearate, titanium dioxide or Lytron 621 (Styrene / Acrylate copolymer); all of which are useful in enhancing the appearance or properties of the product.
[0062] The composition may comprise water in amount of 10 to 96% by weight of the composition, more preferably from 25 to 92%, even more preferably from 42 to 88%, most preferably from 55 to 82% by weight of the composition.P0001302W01 CPL
[0063] 9
[0064] Preferably, the composition has a viscosity of at least 10 mPa s, more preferably in the range 30 to 10000 mPa s, even more preferably 50 to 5000 mPa s, and most preferably 100 to 2000 mPa s, when measured at 20 degrees C at a relatively high shear rate of about 20 s'1.
[0065] Preferably, the composition is an emulsion, more preferably an oil-in-water emulsion. Preferably the composition is a fluid liquid at 25 °C and atmospheric pressure.
[0066] Preferably, the personal care composition is a skin care composition. Skin care composition refers to a composition suitable for topical application to human skin, including leave-on and wash-off products but preferably leave-on compositions. The term “leave-on” as used with reference to compositions herein means a composition that is applied to or rubbed on the skin, and left thereon. The term “wash-off’ as used with reference to compositions herein means a skin cleanser that is applied to or rubbed on the skin and rinsed off substantially immediately subsequent to application. The term "skin" as used herein includes the skin on the face, neck, chest, abdomen, back, arms, under arms, hands, and legs. Preferably “skin” means includes the skin on the face and under arms, more preferably skin means skin on the face other than lips and eyelids. The composition is particularly preferably a moisturizer rather than a make-up product.
[0067] Preferably, the composition is a topical composition. Preferably, the composition may be in the form of cream, lotion, ointment, solution, suspension, emulsion, paste, gel, powder, powder foundation, emulsion foundation, wax foundation, or spray. More preferably, the composition may be formulated in the form of cream, lotion, ointment, emulsion, gel, or a spray.
[0068] Preferably, the composition is capable of upregulating the expression of filaggrin 2 gene by at least 2 folds change, more preferably 2.5 to 15, even more preferably 3 to 12 and still even more preferably 5 to 10 folds change, typically in comparison to same composition except that such composition contains neither carboxymethyl cysteine compound nor urea compound.
[0069] Preferably the use is non-therapeutic. Preferably the method is non-therapeutic. The term non-therapeutic typically means for cosmetic purposes and not curative or therapeutic purposes.
[0070] The following examples are provided to facilitate an understanding of the invention. The examples are not intended to limit the scope of the claims.P0001302W01 CPL
[0071] 10
[0072] Examples
[0073] Example 1
[0074] This example demonstrates upregulation of gene expression by combining hydroxyethyl urea and lysine carboxymethyl cysteinate in certain ratio.
[0075] The normal human epidermal keratinocytes (NHEKs) (Biocell, Xi’an, China, LOT: Ep23073102) were cultured in keratinocyte culture medium (KcGrowth, Biocell, Xi’an, China) and plated in 6-well plates. When the cell confluency reached 40% to 60%, the culture medium was replaced with medium together with or without actives for 24 hours, the total RNA for NHEKs was extracted using RNAex Pro reagent (Accurate Biotechnology, Cat: AG21102) according to manufacturer’s protocol.
[0076] The extracted RNA was quantified using Nanodrop spectrometer (Thermo Fisher Scientific, Waltham, MA, US) and reverse transcribed to generate the template cDNA using the Evo M-MLV RT Premix for qPCR (Accurate Biotechnology, Cat: AG11706) according to manufacturer’s protocol. The expression of FLG2 gene was analyzed by polymerase chain reaction (PCR) using SYBR® Green Premix Pro Taq HS qPCR Kit (Accurate Biotechnology, AG11701). The actin beta (ACTS) gene was selected as the housekeeping gene and all data on relative expression of the target genes was normalized to ACTB gene. The fold changes in expression were calculated relative to the blank control (medium having no active). All tests were conducted at least three times and Table 1 shows the fold change of the gene expression for FLG2.
[0077] Table 1
[0078] Ingredient (% by weight) * Fold changes of FLG2 Sample Ratio of HEU to LCC
[0079] HEUaLCCbgene Expression A (Control) - - - 1.00
[0080] B 0.000005% - - 2.01
[0081] C - 0.00001% - 1.60
[0082] 1 0.000005% 0.00001% 0.5:1 7.80#
[0083] D 0.00005% - - 1.69
[0084] 2 0.00005% 0.00001% 5:1 7.95#
[0085] E 0.0003% - - 1.38
[0086] 3 0.0003% 0.00001% 30:1 3.24#
[0087] G 0.0005% - - 1.37
[0088]
[0089] H 0.0005% 0.00001% 50:1 1.59
[0090] *The level of the ingredients refers the level of active (HEU or LCC) based on the medium, a: LCC: lysine carboxymethyl cysteinate, Hair App®, procured from Sinerga.
[0091] b: HEU: Hydroxyethyl Urea, HYDROVANCE®, procured from Nouryon.
[0092] #: Significantly higher than either of single actives (p < 0.05).P0001302W01 CPL
[0093] 11
[0094] As shown in Table 1, when combining hydroxyethyl urea and lysine carboxymethyl cysteinate in weight ratio according to the present invention (sample 1, 2, and 3), the fold changes are higher than the product of fold changes by single active (for example the fold change for sample 3 is significantly higher than the product of sample E and sample C, 3.24 > 1.38 x 1.60), indicating that the expression of FLG2 gene was synergistically upregulated. In contrast, when combining hydroxyethyl urea and lysine carboxymethyl cysteinate outside the range of the present invention (sample H), the fold change is not higher than the product of fold changes by single active.
Claims
P0001302W01 CPL12Claims1. A personal care composition comprising:(a) carboxymethyl cysteine compound; and(b) urea compound;wherein the weight ratio of the urea compound to the carboxymethyl cysteine compound is no greater than 40:1, and the carboxymethyl cysteine compound is present in amount of no greater than 5% by weight of the composition.
2. The composition according to claim 1 wherein the carboxymethyl cysteine compound comprises carboxymethyl cysteine, ester of carboxymethyl cysteine, and / or salt of carboxymethyl cysteine.
3. The composition according to claim 2 wherein the carboxymethyl cysteine compound comprises salt of carboxymethyl cysteine and preferably the carboxymethyl cysteine compound comprises lysine carboxymethyl cysteinate.
4. The composition according to any one of the preceding claims wherein the carboxymethyl cysteine compound is present in amount of 0.000002% to 5% by weight of the composition, preferably the carboxymethyl cysteine compound is present in amount of 0.002% to 0.6% by weight of the composition.
5. The composition according to any one of the preceding claims wherein the urea compound is selected from urea, and urea with at least one hydrogen substituted by hydroxyalkyl group, preferably the urea compound is urea with at least one hydrogen substituted by Ci- Ce hydroxyalkyl group, more preferably the urea compound is hydroxyethyl urea.
6. The composition according to any one of the preceding claims wherein the urea compound is present in amount of from 0.000001 to 25% by weight of the composition, preferably from 0.01 to 8% by weight of the composition.
7. The composition according to any one of the preceding claims wherein the weight ratio of the urea compound to the carboxymethyl cysteine compound is 1:10 to 40:1, preferably 1:5 to 40: 1 , more preferably 1 :3 to 25: 1.P0001302W01 CPL138. A personal care composition comprising (a) carboxymethyl cysteine compound and (b) urea with at least one hydrogen substituted by Ci-Ce hydroxyalkyl group, wherein the weight ratio of the urea with at least one hydrogen substituted by Ci-Ce hydroxyalkyl group to the carboxymethyl cysteine compound is no greater than 40:1.
9. The composition according to any one of the preceding claims wherein the weight ratio of the urea with at least one hydrogen substituted by Ci-Ce hydroxyalkyl group to the carboxymethyl cysteine compound is 1:10 to 40:1, preferably 1:3 to 25:1.
10. The composition according to any one of the preceding claims wherein the composition comprises fatty acid, preferably the fatty acid is C10-C22 fatty acid, more preferably the fatty acid is selected from lauric acid, palmitic acid, stearic acid or a mixture thereof.
11. The composition according to claim 10 wherein the amount of fatty acid in the composition is preferably from 0.000001 to 25% by weight of the composition, more preferably 0.0001 to 4% by weight of the composition.
12. The composition according to claim 10 or 11 wherein the weight ratio of the urea compound to the fatty acid is 1 :400 to 400: 1 , preferably 1 :40 to 40: 1.
13. The composition according to any one of the preceding claims wherein the composition comprises Vitamin B3 compounds, preferably the vitamin B3 compound is niacinamide.
14. A method of providing the skin benefits selected from the group consisting of enhancing filaggrin production in the skin, improving skin barrier health, upregulating the expression of filaggrin 2 gene comprising a step of topically applying to the skin the composition of any one of the preceding claims.
15. Use of the composition of any one of the preceding claims 1 to 11 for providing the skin benefits selected from the group consisting of enhancing filaggrin production in the skin, improving skin barrier health, upregulating the expression of filaggrin 2 gene.
